1
|
Li L, Yang Z, Lin J, Chen Z, Zhang B, Fu X. Novel Chemiluminescence Immunoassay (CLIA) for the Sensitive Determination of Kidney Injury Molecule-1 in Human Urine. ANAL LETT 2022. [DOI: 10.1080/00032719.2022.2138903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Affiliation(s)
- Lanya Li
- Shuyang Hospital of Traditional Chinese Medicine, Suqian, China
| | | | - Jiayuan Lin
- Jiangsu MDK Biotech. Co., Ltd, Suqian, China
| | | | - Bo Zhang
- Jiangsu MDK Biotech. Co., Ltd, Suqian, China
| | - Xiaoling Fu
- The Second Affiliated Hospital of Nanchang University, Nanchang, China
| |
Collapse
|
2
|
Song L, Xie C, Liu X, Huo Z, Xie Y, Gao J, Zhou S, Shen J, Tang X, Liu X. Development of a Sandwich Chemiluminescence Immunoassay for the Detection of Intact Procollagen Type I N Propeptide with Magnetic Nanosphere Carrier Technology. J Biomed Nanotechnol 2021; 17:1690-1698. [PMID: 34544545 DOI: 10.1166/jbn.2021.3132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The metabolic product of type I collagen synthesis, intact procollagen type I N propeptide (intact PINP), is a potential marker of bone formation and osteoporosis, which is not affected by kidney function. We sought to establish a chemiluminescent immunoassay method for the detection of serum intact PINP with previously prepared paired monoclonal antibodies and to evaluate the diagnostic value of the assay in osteoporosis. Using the capture molecule and monoclonal antibody as detection molecule, a diagnostic reagent was developed to detect intact PINP in serum with magnetic nanosphere carriers by the chemiluminescence method, and its analytical performance in the laboratory was evaluated. Serum intact PINP was measured in 142 healthy people and 115 osteoporosis patients. Results were matched with results of a similar test kit, Roche total PINP Elecsys Chemiluminescent Immunoassay Assay. Compared with the performance of the Roche PINP assay product, our method had higher sensitivity (0.02 ng/mL), wider linear range (0.02-1500 ng/mL), and anti-interference. Serum intact PINP values in osteoporosis patients were significantly higher than in healthy subjects (p < 0.001). Our method had good consistency compared with the Roche PINP assay (r = 0.9794). This chemiluminescence method for detecting serum intact PINP (CLIA-intact PINP) with magnetic nanosphere carrier technology meets the requirements of a clinical testing reagent and is expected to have clinical application after further evaluation and can compete with expensive imported kits on the market.
Collapse
Affiliation(s)
- Li Song
- Clinical Laboratory Medicine, Anhui University of Science & Technology, Huainan, 232001, China
| | - Chunmei Xie
- Department of Blood Transfusion, Guangzhou 8th People's Hospital, Guangzhou Medical University, Guangzhou, 510440, People's Republic of China
| | - Xueke Liu
- Department of Clinical Laboratory Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, 322000, China
| | - Zhen Huo
- Clinical Laboratory Medicine, Anhui University of Science & Technology, Huainan, 232001, China
| | - Yinhai Xie
- Clinical Laboratory Medicine, Anhui University of Science & Technology, Huainan, 232001, China
| | - Jiafeng Gao
- Clinical Laboratory Medicine, Anhui University of Science & Technology, Huainan, 232001, China
| | - Shuping Zhou
- Clinical Laboratory Medicine, Anhui University of Science & Technology, Huainan, 232001, China
| | - Jing Shen
- Clinical Laboratory Medicine, Anhui University of Science & Technology, Huainan, 232001, China
| | - Xiaolong Tang
- Clinical Laboratory Medicine, Anhui University of Science & Technology, Huainan, 232001, China
| | - Xinkuang Liu
- Clinical Laboratory Medicine, Anhui University of Science & Technology, Huainan, 232001, China
| |
Collapse
|
3
|
Zhang L, Zhou X, Dai Y, Lv C, Wu J, Wu Q, Li T, Wang Y, Xia P, Pei H, Huang B. Establishment of interleukin-18 time-resolved fluorescence immunoassay and its preliminary application in liver disease. J Clin Lab Anal 2021; 35:e23758. [PMID: 33720453 PMCID: PMC8128310 DOI: 10.1002/jcla.23758] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Revised: 02/01/2021] [Accepted: 02/27/2021] [Indexed: 12/30/2022] Open
Abstract
Background To establish a time‐resolved fluorescence immunoassay of interleukin (IL)‐18 (IL‐18‐TRFIA) and detect its concentration in different liver disease serum samples. Methods The IL‐18 coating antibody and the Eu3+‐labeled detection antibody were used for the IL‐18‐TRFIA to detect serum IL‐18 concentration in patients with liver cancer, hepatitis B, hepatitis C, autoimmune hepatitis, fatty liver disease, and healthy controls. The double‐antibody sandwich method was used and methodological evaluation was performed. Results The average intra‐ and inter‐assay coefficient of variation for IL‐18‐TRFIA was 4.80% and 5.90%, respectively. The average recovery rate was 106.19 ± 3.44%. The sensitivity (10.96 pg/mL) was higher than that obtained using the ELISA method (62.5 pg/mL). The detection range was 10.96–1000 pg/mL. IL‐6 and galectin‐3 did not cross‐react with IL‐18‐TRFIA. The serum concentration of IL‐18 was (776.99; 653.48–952.39 pg/mL) in hepatitis C, (911; 775.55–1130.03 pg/mL) in fatty liver, (1048.88; 730.04–1185.10 pg/mL) in liver cancer, and (949.12; 723.70–1160.28 pg/mL) in hepatitis B. Moreover, IL‐18 serum levels were significantly higher in patients than the healthy controls (483.09; 402.52–599.70/mL) (p < 0.0001). Autoimmune hepatitis with a serum IL‐18 concentration of 571.62; 502.47–730.31 pg/mL was not significantly different from the healthy controls (p > 0.05). Conclusion We established a highly sensitive IL‐18‐TRFIA method that successfully detected serum IL‐18 concentrations in different liver diseases. Furthermore, IL‐18 serum concentration was higher in patients with liver cancer, hepatitis C, hepatitis B, and fatty liver disease compared to healthy controls.
Collapse
Affiliation(s)
- Li Zhang
- College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China
| | - Xiumei Zhou
- College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China
| | - Yaping Dai
- Wuxi No. 5 People's Hospital, Wuxi, China
| | - Chunyan Lv
- Wuxi No. 5 People's Hospital, Wuxi, China
| | - Jian Wu
- Department of Laboratory Medicine, The First People's Hospital of Yancheng City, Yancheng, China
| | - Qingqing Wu
- College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China
| | - Ting Li
- College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China
| | - Yigang Wang
- College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China
| | - Penguo Xia
- College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China
| | - Hao Pei
- Wuxi No. 5 People's Hospital, Wuxi, China
| | - Biao Huang
- College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China
| |
Collapse
|
4
|
Li Z, Liu Q, Li Y, Yuan W, Y.Li F. One-step polymerized lanthanide-based polystyrene microsphere for sensitive lateral flow immunoassay. J RARE EARTH 2021. [DOI: 10.1016/j.jre.2020.06.020] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
5
|
Han S, Xue Y, Zhang J, Huang J, Liu X, Yang Y, Bai Z, Wang C. A Chemiluminescent Immunoassay for Osteocalcin in Human Serum and a Solution to the "Hook Effect". JOURNAL OF ANALYTICAL METHODS IN CHEMISTRY 2020; 2020:8891437. [PMID: 33376621 PMCID: PMC7744234 DOI: 10.1155/2020/8891437] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 08/15/2020] [Accepted: 10/09/2020] [Indexed: 06/12/2023]
Abstract
A chemiluminescent immunoassay for human serum osteocalcin, or bone Gla protein, was established using a double-antibody sandwich model. Examination of the hook effect revealed that it was significantly reduced, and no hook effect was observed at an osteocalcin concentration of 4000 ng/mL. The established method showed good analytical performance and thermal stability. The limit of detection was 0.03 ng/mL. The intra-assay coefficient of variation (CV) was 3.22%-5.64%, the interassay CV was 4.42%-7.25%, and the recovery rate was 93.22%-107.99%. Cross-reactivity (CR) was not observed with bovine, rat, mouse, rabbit, or porcine samples. The developed method showed a good correlation with the N-MID product from Roche. In total, 1069 clinical patient samples were measured using the reagent kit developed in this study.
Collapse
Affiliation(s)
- Shuang Han
- The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, China
- National Engineering Laboratory for Cereal Fermentation Technology, Jiangnan University, Wuxi, China
- Jiangsu Provincial Research Center for Bioactive Product Processing Technology, Jiangnan University, Wuxi 214122, China
| | - Yifeng Xue
- The Affiliated Wuxi People's Hospital of Nanjing Medical University, Department of Laboratory Medicine, Wuxi, China
| | - Junlan Zhang
- The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, China
- National Engineering Laboratory for Cereal Fermentation Technology, Jiangnan University, Wuxi, China
- Jiangsu Provincial Research Center for Bioactive Product Processing Technology, Jiangnan University, Wuxi 214122, China
| | - Jianrong Huang
- The Affiliated Wuxi People's Hospital of Nanjing Medical University, Department of Laboratory Medicine, Wuxi, China
| | - Xiuxia Liu
- The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, China
- National Engineering Laboratory for Cereal Fermentation Technology, Jiangnan University, Wuxi, China
- Jiangsu Provincial Research Center for Bioactive Product Processing Technology, Jiangnan University, Wuxi 214122, China
| | - Yankun Yang
- The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, China
- National Engineering Laboratory for Cereal Fermentation Technology, Jiangnan University, Wuxi, China
- Jiangsu Provincial Research Center for Bioactive Product Processing Technology, Jiangnan University, Wuxi 214122, China
| | - Zhonghu Bai
- The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi 214122, China
- National Engineering Laboratory for Cereal Fermentation Technology, Jiangnan University, Wuxi, China
- Jiangsu Provincial Research Center for Bioactive Product Processing Technology, Jiangnan University, Wuxi 214122, China
| | - Chunxin Wang
- The Affiliated Wuxi People's Hospital of Nanjing Medical University, Department of Laboratory Medicine, Wuxi, China
| |
Collapse
|
6
|
Awaludin N, Abdullah J, Salam F, Ramachandran K, Yusof NA, Wasoh H. Fluorescence-based immunoassay for the detection of Xanthomonas oryzae pv. oryzae in rice leaf. Anal Biochem 2020; 610:113876. [PMID: 32750357 DOI: 10.1016/j.ab.2020.113876] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Revised: 07/07/2020] [Accepted: 07/14/2020] [Indexed: 12/13/2022]
Abstract
The identification of rice bacterial leaf blight disease requires a simple, rapid, highly sensitive, and quantitative approach that can be applied as an early detection monitoring tool in rice health. This paper highlights the development of a turn-off fluorescence-based immunoassay for the early detection of Xanthomonas oryzae pv. oryzae (Xoo), a gram-negative bacterium that causes rice bacterial leaf blight disease. Antibodies against Xoo bacterial cells were produced as specific bio-recognition molecules and the conjugation of these antibodies with graphene quantum dots and gold nanoparticles was performed and characterized, respectively. The combination of both these bio-probes as a fluorescent donor and metal quencher led to changes in the fluorescence signal. The immunoreaction between AntiXoo-GQDs, Xoo cells, and AntiXoo-AuNPs in the immuno-aggregation complex led to the energy transfer in the turn-off fluorescence-based quenching system. The change in fluorescence intensity was proportional to the logarithm of Xoo cells in the range of 100-105 CFU mL-1. The limit of detection was achieved at 22 CFU mL-1 and the specificity test against other plant disease pathogens showed high specificity towards Xoo. The detection of Xoo in real plant samples was also performed in this study and demonstrated satisfactory results.
Collapse
Affiliation(s)
- Norhafniza Awaludin
- Institute of Advanced Technology, University of Putra Malaysia, 43400, Serdang, Selangor, Malaysia; Biotechnology & Nanotechnology Research Centre, Malaysian Agricultural Research and Development Institute, Persiaran MARDI-UPM, 43400, Serdang, Selangor, Malaysia
| | - Jaafar Abdullah
- Institute of Advanced Technology, University of Putra Malaysia, 43400, Serdang, Selangor, Malaysia; Department of Chemistry, Faculty of Science, University of Putra Malaysia, 43400, Serdang, Selangor, Malaysia.
| | - Faridah Salam
- Biotechnology & Nanotechnology Research Centre, Malaysian Agricultural Research and Development Institute, Persiaran MARDI-UPM, 43400, Serdang, Selangor, Malaysia
| | - Kogeethavani Ramachandran
- Paddy & Rice Research Centre, Malaysian Agricultural Research and Development Institute, MARDI Seberang Perai, Beg Berkunci No.203, Pejabat Pos Kepala Batas, 13200, Seberang Perai, Pulau Pinang, Malaysia
| | - Nor Azah Yusof
- Institute of Advanced Technology, University of Putra Malaysia, 43400, Serdang, Selangor, Malaysia; Department of Chemistry, Faculty of Science, University of Putra Malaysia, 43400, Serdang, Selangor, Malaysia
| | - Helmi Wasoh
- Department of Bioprocess Technology, Faculty of Biotechnology and Biomolecule Science, University of Putra Malaysia, 43400, Serdang, Selangor, Malaysia
| |
Collapse
|
7
|
Wang G, Wan Y, Lin G, Li Z, Dong Z, Liu T. Development of a novel chemiluminescence immunoassay for the detection of procalcitonin. J Immunol Methods 2020; 484-485:112829. [PMID: 32673618 DOI: 10.1016/j.jim.2020.112829] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Revised: 06/08/2020] [Accepted: 07/09/2020] [Indexed: 01/28/2023]
Abstract
OBJECTIVE To evaluate the analytical performance of our previously developed chemiluminescence immunoassay (CLIA) kit for the detection of procalcitonin (PCT) and compare with the results obtained using the Vidas B.R.A.H.M.S. PCT™ test (PCT-V). DESIGN AND METHODS Our laboratory previously designed a novel CLIA kit and supporting instrument (AE-180) for the detection of PCT. We analyzed the clinical performance of this system, including the imprecision, limit of detection, and linearity of analyses of 305 serum specimens. The results were compared with measurements of the same serum samples obtained with PCT-V. RESULTS The limit of detection and blank of our kit were 0.0075 and 0.0039 ng/mL, respectively. The intra- and inter-assay coefficient of variation of the kit were both between 0.8% and 3.9%. The equation of linearity was found to be y = 1.03× + 0.06 (r = 0.99) for concentrations in the range of 0.01-110 ng/mL. The correlation coefficient with the results of PCT-V was 0.995, and the equation obtained for Passing and Bablok regression analysis was 1.061 for our CLIA PCT kit and - 0.003 for PCT-V. Our kit slightly overestimated the concentration according to comparison with PCT-V results. CONCLUSION The kit that was previously developed in our laboratory for the measurement of serum PCT concentration using CLIA technology shows excellent performance, just that the functional sensitivity is not as good as the PCT-V; therefore, we suggest that this kit is suitable for clinical use.
Collapse
Affiliation(s)
- Gang Wang
- Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong, PR China
| | - Yong Wan
- Research Institute, Guangzhou Darui Biotechnology Co., Ltd., Guangzhou 510507, Guangdong, PR China
| | - Guanfeng Lin
- Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong, PR China
| | - Zhixiong Li
- Research Institute, Guangzhou Darui Biotechnology Co., Ltd., Guangzhou 510507, Guangdong, PR China
| | - Zhining Dong
- Research Institute, Guangzhou Darui Biotechnology Co., Ltd., Guangzhou 510507, Guangdong, PR China
| | - Tiancai Liu
- Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, Guangdong, PR China; Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, Southern Medical University, Guangzhou 510515, Guangdong, PR China.
| |
Collapse
|
8
|
Zhang Z, Yuan F, Chen R, Li Y, Ma J, Yan X, Wang L, Zhang F, Tao H, Guo D, Huang Z, Zhang S, Li X, Zhi X, Ge X, Hu Y, Wang J. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors. Front Immunol 2020; 11:1173. [PMID: 32587591 PMCID: PMC7298878 DOI: 10.3389/fimmu.2020.01173] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Accepted: 05/12/2020] [Indexed: 12/11/2022] Open
Abstract
Background: Serum tumor markers carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cytokeratin 19 fragment (CYFRA21-1) and squamous-cell carcinoma-related antigen (SCC-Ag) are routinely used for monitoring the response to chemotherapy or targeted therapy in advanced-stage non-small cell lung cancer (NSCLC), however their role in immunotherapy remains unclear. The aim of this study was to investigate whether dynamics of these serum markers were associated with the efficacy and prognosis of Chinese late-stage NSCLC patients treated with programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors. Methods: We initiated a longitudinal prospective study on advanced NSCLC patients treated with PD-1/PD-L1 inhibitors in Chinese PLA general hospital (Beijing, China). Blood samples of baseline and after 6 weeks' treatment were collected. CT scan were used by all patients to evaluate treatment efficacy according to RECIST 1.1. Serum tumor markers levels were measured with an electrochemical luminescence for SCC-Ag and with a chemiluminescent microparticle immunoassay for serum CEA, CA125, and CYFRA21-1. At least 20% decreases of the biomarkers from baseline were considered as meaningful improvements after 6 weeks of treatment with immune checkpoint inhibitors (ICIs). Optimization-based method was used to balance baseline covariates between different groups. Associations between serum tumor biomarker improvements and objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were analyzed. Results: A total of 308 Chinese patients with advanced NSCLC were enrolled in the study. After balancing baseline covariates, patients with meaningful improvements in <2 out of 4 biomarkers (CEA, CA125, CYFRA21-1, and SCC-Ag) was ended up with lower ORR (0.08 vs. 0.35, p < 0.001), shorten PFS (median: 5.4 vs. 12.5 months, p < 0.001), and OS (median: 11.7 vs. 25.6 months, p < 0.001) in the total population. Subgroup analysis of patients with adenocarcinoma revealed that patients with meaningful improvements in <2 out of 4 biomarkers had significant lower ORR (0.06 vs. 0.36, p < 0.001), shorten PFS (median: 4.1 vs. 11.9 months, p < 0.001), and OS (median: 11.9 vs. 24.2 months, p < 0.001). So as in patients with squamous cell carcinoma, meaningful improvements in at least 2 out of 4 biomarkers were linked to better ORR (0.42 vs. 0.08, p = 0.014), longer PFS (median: 13.1 vs. 5.6 months, p = 0.001), and OS (median: 25.6 vs. 10.9 months, p = 0.06). Conclusions: The dynamic change of CEA, CA125, CYFRA21-1, and SCC-Ag from baseline have prognostic value for late-stage NSCLC patients treated with PD-1/PD-L1 inhibitors. Decrease of associated biomarkers serum levels were associated with favorable clinical outcomes.
Collapse
Affiliation(s)
- Zhibo Zhang
- Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.,Medical School of Chinese PLA, Beijing, China.,The 78th Group Army Hospital of Chinese PLA, Mudanjiang, China
| | - Fang Yuan
- Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Runzhe Chen
- Departments of Thoracic/Head and Neck Medical Oncology and Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Ye Li
- Department of Radiotherapy, The First Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Junxun Ma
- Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Xiang Yan
- Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Lijie Wang
- Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Fan Zhang
- Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Haitao Tao
- Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Dong Guo
- BeiGene (Shanghai) Co., Ltd., Shanghai, China
| | | | - Sujie Zhang
- Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Xiaoyan Li
- Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Xiaoyu Zhi
- Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.,Medical School of Chinese PLA, Beijing, China
| | - Xiangwei Ge
- Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.,Medical School of Chinese PLA, Beijing, China
| | - Yi Hu
- Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Jinliang Wang
- Department of Oncology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
| |
Collapse
|